Pharmacological significance of glycosylation in therapeutic proteins.

[1]  T. Gerngross,et al.  Glycosylation engineering in yeast: the advent of fully humanized yeast. , 2007, Current opinion in biotechnology.

[2]  K. Shitara,et al.  The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity* , 2003, The Journal of Biological Chemistry.

[3]  R. Kunert,et al.  A plant-derived human monoclonal antibody induces an anti-carbohydrate immune response in rabbits. , 2007, Glycobiology.

[4]  Shigeru Iida,et al.  Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody‐dependent cellular cytotoxicity , 2004, Biotechnology and bioengineering.

[5]  B. van den Hazel,et al.  Glycosylation of an N-terminal extension prolongs the half-life and increases the in vivo activity of follicle stimulating hormone. , 2003, The Journal of clinical endocrinology and metabolism.

[6]  Youwei Jiang,et al.  Optimization of humanized IgGs in glycoengineered Pichia pastoris , 2006, Nature Biotechnology.

[7]  D. C. Linch,et al.  Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF , 1990, The Lancet.

[8]  S. Withers,et al.  Designer enzymes for glycosphingolipid synthesis by directed evolution. , 2009, Nature chemical biology.

[9]  Teresa Mitchell,et al.  Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: production of complex humanized glycoproteins with terminal galactose. , 2004, Glycobiology.

[10]  P. Parren,et al.  Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. , 2008, Blood.

[11]  S. Müller,et al.  Recombinant MUC1 Probe Authentically Reflects Cell-specific O-Glycosylation Profiles of Endogenous Breast Cancer Mucin , 2002, The Journal of Biological Chemistry.

[12]  R. Dwek,et al.  Glycosylation and the immune system. , 2001, Science.

[13]  S. Elliott,et al.  Control of rHuEPO biological activity: the role of carbohydrate. , 2004, Experimental hematology.

[14]  Y. Chiba,et al.  Glycan engineering and production of 'humanized' glycoprotein in yeast cells. , 2009, Biological & pharmaceutical bulletin.

[15]  J. Davies,et al.  Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. , 2001, Biotechnology and bioengineering.

[16]  J. Mermod,et al.  Site-specific O-glycosylation of human granulocyte/macrophage colony-stimulating factor secreted by yeast and animal cells. , 1992, European journal of biochemistry.

[17]  J. Lustbader,et al.  Effects of long-acting recombinant human follicle-stimulating hormone analogs containing N-linked glycosylation on murine folliculogenesis. , 2005, Fertility and sterility.

[18]  Scott Estes,et al.  Development of a simple and rapid method for producing non‐fucosylated oligomannose containing antibodies with increased effector function , 2008, Biotechnology and bioengineering.

[19]  S. Iida,et al.  Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils. , 2009, Experimental hematology.

[20]  R. Horstkorte,et al.  Increasing the sialylation of therapeutic glycoproteins: the potential of the sialic acid biosynthetic pathway. , 2009, Journal of pharmaceutical sciences.

[21]  Quynh-Thu Le,et al.  Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. , 2008, The New England journal of medicine.

[22]  J. Taylor‐Papadimitriou,et al.  The ST6GalNAc-I Sialyltransferase Localizes throughout the Golgi and Is Responsible for the Synthesis of the Tumor-associated Sialyl-Tn O-Glycan in Human Breast Cancer* , 2006, Journal of Biological Chemistry.

[23]  A. Hsueh,et al.  Enhanced stimulation of follicle maturation and ovulatory potential by long acting follicle-stimulating hormone agonists with extended carboxyl-terminal peptides. , 1992, Endocrinology.

[24]  T. Wurch,et al.  Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. , 2008, Current pharmaceutical biotechnology.

[25]  H. Kozutsumi,et al.  Relationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[26]  L. Presta,et al.  Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity* , 2002, The Journal of Biological Chemistry.

[27]  M. Takeuchi,et al.  Role of antennary structure of N-linked sugar chains in renal handling of recombinant human erythropoietin. , 1995, Blood.

[28]  A. Helenius,et al.  Intracellular functions of N-linked glycans. , 2001, Science.

[29]  Roy Jefferis,et al.  Glycosylation as a strategy to improve antibody-based therapeutics , 2009, Nature Reviews Drug Discovery.

[30]  Stacey Ma,et al.  Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content. , 2008, Biologicals : journal of the International Association of Biological Standardization.

[31]  Lihua Huang,et al.  Impact of variable domain glycosylation on antibody clearance: an LC/MS characterization. , 2006, Analytical biochemistry.

[32]  R. Kontermann,et al.  N-Glycosylation as Novel Strategy to Improve Pharmacokinetic Properties of Bispecific Single-chain Diabodies* , 2008, Journal of Biological Chemistry.

[33]  S. Elliott,et al.  Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. , 2005, Journal of pharmaceutical sciences.

[34]  M. Butler,et al.  Optimisation of the Cellular Metabolism of Glycosylation for Recombinant Proteins Produced by Mammalian Cell Systems , 2006, Cytotechnology.

[35]  Susan C. Brown,et al.  Defective glycosylation in muscular dystrophy , 2002, The Lancet.

[36]  James E. Bailey,et al.  Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity , 1999, Nature Biotechnology.

[37]  Jack Hoopes,et al.  Humanization of Yeast to Produce Complex Terminally Sialylated Glycoproteins , 2006, Science.

[38]  D. Danilenko,et al.  Evidence for an Asialoglycoprotein Receptor on Nonparenchymal Cells for O-Linked Glycoproteins , 2008, Journal of Pharmacology and Experimental Therapeutics.

[39]  S. Iida,et al.  The N-linked oligosaccharide at FcγRIIIa Asn-45: an inhibitory element for high FcγRIIIa binding affinity to IgG glycoforms lacking core fucosylation , 2008, Glycobiology.

[40]  Z. Li,et al.  Optimal and consistent protein glycosylation in mammalian cell culture. , 2009, Glycobiology.

[41]  P. Lerouge,et al.  Immunoreactivity in mammals of two typical plant glyco-epitopes, core alpha(1,3)-fucose and core xylose. , 2003, Glycobiology.

[42]  M. J. Bailey,et al.  Identification and quantification of N-linked oligosaccharides released from glycoproteins: an inter-laboratory study. , 2008, Glycobiology.

[43]  A. Hsueh,et al.  Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[44]  S. Withers,et al.  Emerging methods for the production of homogeneous human glycoproteins. , 2009, Nature chemical biology.

[45]  R. Ogden,et al.  Development and characterization of a long-acting recombinant hFSH agonist. , 2003, Human reproduction.

[46]  P. Devroey,et al.  Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. , 2004, The Journal of clinical endocrinology and metabolism.

[47]  Teresa Mitchell,et al.  Production of Complex Human Glycoproteins in Yeast , 2003, Science.

[48]  T. Endo.  O-mannosyl glycans in mammals. , 1999, Biochimica et biophysica acta.

[49]  L. Gardner,et al.  Leukocyte extravasation: chemokine transport and presentation by the endothelium. , 2002, Blood.

[50]  Teresa Mitchell,et al.  Production of monoclonal antibodies by glycoengineered Pichia pastoris. , 2009, Journal of biotechnology.

[51]  Leonard G Presta,et al.  Molecular engineering and design of therapeutic antibodies. , 2008, Current opinion in immunology.

[52]  A. Herscovics.  Processing glycosidases of Saccharomyces cerevisiae. , 1999, Biochimica et biophysica acta.

[53]  Byung-Kwon Choi,et al.  Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[54]  R. Jefferis,et al.  Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. , 2009, Trends in pharmacological sciences.

[55]  K. Campbell,et al.  Dystroglycan: from biosynthesis to pathogenesis of human disease , 2006, Journal of Cell Science.

[56]  J. Baenziger,et al.  Pituitary glycoprotein hormone oligosaccharides: structure, synthesis and function of the asparagine-linked oligosaccharides on lutropin, follitropin and thyrotropin. , 1988, Biochimica et biophysica acta.

[57]  M. Rogge,et al.  Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers. , 1995, Therapeutic immunology.

[58]  R. Ogden,et al.  Long-acting follicle-stimulating hormone analogs containing N-linked glycosylation exhibited increased bioactivity compared with o-linked analogs in female rats. , 2004, The Journal of clinical endocrinology and metabolism.

[59]  L. Lehle,et al.  The oligosaccharyltransferase complex from yeast. , 1999, Biochimica et biophysica acta.

[60]  S. Kornfeld,et al.  Assembly of asparagine-linked oligosaccharides. , 1985, Annual review of biochemistry.

[61]  A. Woods,et al.  The role of syndecans in disease and wound healing. , 2006, Matrix biology : journal of the International Society for Matrix Biology.

[62]  Terrance A Stadheim,et al.  Challenges in therapeutic glycoprotein production. , 2006, Current opinion in biotechnology.

[63]  J. M. Beals,et al.  Glycosylation of erythropoietin affects receptor binding kinetics: role of electrostatic interactions. , 2002, Biochemistry.

[64]  D. Casley,et al.  O-glycosylation delays the clearance of human IGF-binding protein-6 from the circulation. , 2000, European journal of endocrinology.

[65]  T. Gerngross,et al.  Advances in the production of human therapeutic proteins in yeasts and filamentous fungi , 2004, Nature Biotechnology.

[66]  S. Wildt,et al.  The humanization of N-glycosylation pathways in yeast , 2005, Nature Reviews Microbiology.

[67]  M. Aebi,et al.  The dolichol pathway of N-linked glycosylation. , 1999, Biochimica et biophysica acta.